FREMONT, CA--(MARKET WIRE)--Oct 10, 2008 -- Cardima, Inc. (OTC BB:CADM.OB - News), has established a new strategic surgical relationship and renewed the electrophysiology sales and marketing contract with Biocore, a U.S. Eastern regional sales agent specializing in sales and customer training and support for Cardiac Devices. Biocore’s staff will be directly supporting both surgical and cardiac cath lab procedures, as well as assisting cardiac surgeons and electrophysiologists with Cardima’s solutions for patient care. This relationship will strengthen Cardima’s Surgical Program commercial launch in the U.S.A. by leveraging the existing relationships Biocore has with physicians and hospitals in the eastern United States.
In commenting on this partnership, Cardima’s CEO, Robert Cheney, stated, “Biocore has over 20 years of experience in this field and complementary relationships with our key surgical customers. With Biocore’s experience in the ablation and diagnostic markets, they will strengthen Cardima’s market presence in the eastern United States. Their track record for providing customer support and sales growth makes Biocore an ideal partner to represent and support Cardima’s EP and surgical products.”
Timothy Lockner, President of Biocore, has represented companies such as St. Jude Medical, Medtronic, ATS Medical, EP MedSystems, Gish Biomedical, Maquet, CHF Solutions, Cas Medical Systems, and Peters/DC. He has extensive sales management experience and has built a successful business as an independent sales agent. In commenting about the extension of this contract, Mr. Lockner stated, “Cardima has diagnostic products that have withstood the test of time and continue to play an important role in advanced EP procedures. We now look forward to building the surgical market, in particular the minimally invasive stand alone AF procedure, for Cardima’s superior Surgical Ablation System. In addition to the stand alone market, Cardima’s Surgical Ablation System offers significant advantages in the ‘open chest’ concomitant market and we will aggressively enter this existing market as well.”
About Cardima
Cardima, Inc. has developed the PATHFINDER®, TRACER(TM) and REVELATION® Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series of guiding catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.
PATHFINDER®, TRACER(TM), VUEPORT®, NAVIPORT®, REVELATION® and INTELLITEMP® are registered trademarks of Cardima, Inc.
For more information, please visit the Company’s website at www.cardima.com.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.
Contact:
Dr. Richard Gaston Cardima, Inc. (510) 354-0300 http://www.Cardima.com
Source: Cardima, Inc.
